L
Laigo Bio
Bispecific antibodies for targeted membrane protein degradation
About Laigo Bio
Laigo Bio is a Utrecht biotechnology company founded in 2021 from Oncode Institute and Argobio Studio research by Professor Madelon Maurice (UMC Utrecht), developing the SureTAC bispecific-antibody platform for targeted membrane protein degradation via lysosomal pathways in oncology, autoimmune and inflammatory disease. The approach aims to remove previously hard-to-drug cell-surface targets with deeper sustained pathway inhibition than conventional antibodies; pipeline work includes PD-L1, VEGF and Wnt-pathway programmes plus immunology candidates for autoimmunity and graft rejection, led by CEO Dr Matthew Baker. After an initial €11.5 million seed close in December 2025 co-led by Kurma Partners and Curie Capital with Argobio Studio, Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Region and Cancer Research Horizons, Laigo Bio completed a final close in March 2026 bringing the oversubscribed seed to €17 million with new co-lead Biovance Capital (€4 million) and additional Kurma capital. Sources: company / Kurma / Biovance Capital Dec 2025–Mar 2026; EU-Startups.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Utrecht, Netherlands
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 87.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Immune System, Spinout, Biotech and Pharma, Woman Founder, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Mar 2026 | $6M | $63M | Biovance Capital Partners · Kurma Partners | ↗ |
| SEED✓Equity / VC | Dec 2025 | $13M | $51M | Angelini Ventures · Oncode Oncology Bridge Fund · Cancer Research UK · Argobio Studio | ↗ |
Growth signals
Latest recorded traffic for Laigo Bio is 190 monthly website visits, down 66.7% over the last three months. Laigo Bio's team grew 214.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed10 investors entered at this stage
Kurma Partners
Curie Capital
Angelini Ventures- OFOncode Oncology Bridge Fund
Cancer Research UK
Argobio Studio
Eurazeo
ROM Utrecht Region - Regional Development Agency
Cancer Research Horizon
Biovance Capital Partners
Other known investors1 additional known investor
UMC Utrecht
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Laigo Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Laigo Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.